skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectives

Review

(3075) Views  (789) Full article downloads

Authors: Pierre Costa, Thierry Grivel, Naji Gehchan

Published Date April 2009 Volume 2009:3 Pages 105 - 111
DOI: http://dx.doi.org/10.2147/PPA.S3937

Pierre Costa1, Thierry Grivel2, Naji Gehchan3

1Service d’Urologie–Andrologie, Hôpital Caremeau, Nîmes, France; 2159, Avenue Sainte-Marguerite, Nice, France; 3Eli Lilly and Company, Lilly France – Medical Division, Suresnes, France

Abstract: Erectile dysfunction (ED) is a prevalent condition that affects men and their partners. Significant improvements in the sexual lives of these couples have been achieved with the introduction of phosphodiesterase 5 (PDE5) inhibitors. A PDE5 inhibitor is now widely recognized as the first-line therapy for the majority of men with ED. Currently, three PDE5 inhibitors – sildenafil, tadalafil and vardenafil – are approved to be taken as needed in anticipation of sexual activity, but only one of these, tadalafil, has been approved to be taken once daily. The primary aims of this review are to summarize the patients’ and partners’ viewpoints of ED management with PDE5 inhibitors, and to determine whether once-daily tadalafil can contribute to improving some psychological aspects of ED (such as sexual self-confidence, spontaneity and time concerns) compared with on-demand tadalafil or other PDE5 inhibitors taken by patients with ED.

Keywords: erectile dysfunction, once-daily treatment, patient and partner perspectives, phosphodiesterase 5 (PDE5) inhibitor








Readers of this article also read:

Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction
Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil
Developing anchored measures of patient satisfaction with pharmaceutical care delivery: Experiences versus expectations
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy
Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: Safety, tolerability, and efficacy
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Erratum